BioInvent International AB (BioInvent), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces it has received Investigational New Drug (IND) approval for the monoclonal antibody BI-1910, which will now become its second anti-tumour necrosis factor receptor 2 (TNFR2) programme to enter clinical development.
BI-1910 offers a differentiated, agonist approach to cancer treatment compared to BI-1808, BioInvent
